Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

24-month EFS 67.8% vs 59.8%, HR 0.68 (0.56-0.82), P<0.001.

N Engl J Med 2024;391(19):1773-1786.PubMed 39282910